Aardvark Adventures Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Aardvark Adventures

DAVE 207.00

-1.5%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: ~digs	3/27/2007 2:33:08 AM
	of 7944

INO - Inovio Biomedical Corporation engages in the development and commercialization of medical therapies to address various diseases with critical unmet treatment needs using electroporation therapy. The therapy aims at selective killing of cancer cells and local ablation of solid tumors, while preserving healthy tissue. Its Selective Electrochemical Tumor Ablation (SECTA) therapy, including MedPulser, which is in Phase III clinical trials, comprises sites in the United States and Europe for the treatment of recurrent head and neck cancer. The system delivers electrical pulses to tumors injected with the generic drug bleomycin. The company also develops devices for the delivery of DNA for vaccinations and gene therapy. It has partnerships primarily with Merck & Co., Inc.; Vical Incorporated; University of South Florida Research Foundation, Inc.; and Tripep AB. Monday March 26, 6:00 am ET Inovio Biomedical's DNA Delivery Technology Significantly Enhances Potency of HIV DNA Vaccine biz.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next